Opaleye Management Inc. Takes $1.06 Million Position in Pasithea Therapeutics Corp. $KTTA

Opaleye Management Inc. acquired a new position in Pasithea Therapeutics Corp. (NASDAQ:KTTA) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 2,050,000 shares of the company’s stock, valued at approximately $1,057,000. Opaleye Management Inc. owned approximately 0.06% of Pasithea Therapeutics at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Janus Henderson Group PLC bought a new stake in Pasithea Therapeutics during the fourth quarter valued at about $2,720,000. Vivo Capital LLC bought a new position in shares of Pasithea Therapeutics in the fourth quarter worth about $2,709,000. Squadron Capital Management LLC bought a new position in shares of Pasithea Therapeutics in the fourth quarter worth about $2,709,000. Adage Capital Partners GP L.L.C. purchased a new position in shares of Pasithea Therapeutics during the 4th quarter valued at about $2,709,000. Finally, Persistent Asset Partners Ltd purchased a new position in shares of Pasithea Therapeutics during the 4th quarter valued at about $375,000. 23.92% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on KTTA shares. Zacks Research lowered shares of Pasithea Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 17th. HC Wainwright reiterated a “buy” rating and issued a $3.00 price target on shares of Pasithea Therapeutics in a research report on Tuesday, June 16th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Pasithea Therapeutics in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $3.00.

Pasithea Therapeutics Trading Down 5.2%

Shares of KTTA stock opened at $0.54 on Friday. The stock has a market capitalization of $18.04 million, a price-to-earnings ratio of -0.34 and a beta of 0.33. Pasithea Therapeutics Corp. has a 12-month low of $0.28 and a 12-month high of $2.06. The stock’s 50-day moving average price is $0.50 and its 200-day moving average price is $0.64.

Pasithea Therapeutics (NASDAQ:KTTA) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.16) EPS for the quarter, meeting analysts’ consensus estimates of ($0.16). As a group, research analysts predict that Pasithea Therapeutics Corp. will post -0.76 EPS for the current fiscal year.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics, Inc (NASDAQ: KTTA) is a clinical?stage biopharmaceutical company focused on the discovery, development and eventual commercialization of engineered antibody therapeutics for immunological diseases. Leveraging a proprietary discovery engine that integrates advanced computational biology, high-throughput screening and structural analysis, the company aims to identify and generate novel therapeutic molecules that modulate key immune pathways.

The company’s pipeline consists of multiple preclinical and early clinical candidates targeting autoimmune and inflammatory disorders.